507 related articles for article (PubMed ID: 33552945)
21. Construction and experimental validation of a B cell-related gene signature to predict the prognosis and immunotherapeutic sensitivity in bladder cancer.
Zhou R; Zhou J; Muhuitijiang B; Zeng X; Tan W
Aging (Albany NY); 2023 Jun; 15(12):5355-5380. PubMed ID: 37379131
[TBL] [Abstract][Full Text] [Related]
22. Comprehensive Exploration of Tumor Microenvironment Modulation Based on the ESTIMATE Algorithm in Bladder Urothelial Carcinoma Microenvironment.
Chen J; Lv B; Zhan Y; Zhu K; Zhang R; Chen B; Jin Y; Li Y; Zheng J; Lin C
Front Oncol; 2022; 12():724261. PubMed ID: 35237505
[TBL] [Abstract][Full Text] [Related]
23. Investigating the impact of regulatory B cells and regulatory B cell-related genes on bladder cancer progression and immunotherapeutic sensitivity.
Zhou J; Zhou R; Zhu Y; Deng S; Muhuitijiang B; Li C; Shi X; Zhang L; Tan W
J Exp Clin Cancer Res; 2024 Apr; 43(1):101. PubMed ID: 38566204
[TBL] [Abstract][Full Text] [Related]
24. Robust pyroptosis risk score guides the treatment options and predicts the prognosis of bladder carcinoma.
Deng D; Liu F; Liu Z; Wu Z; He Y; Zhang C; Zu X; Ou Z; Wang Y
Front Immunol; 2022; 13():965469. PubMed ID: 36090967
[TBL] [Abstract][Full Text] [Related]
25. A potential prognostic lncRNA signature for predicting survival in patients with bladder urothelial carcinoma.
Bao Z; Zhang W; Dong D
Oncotarget; 2017 Feb; 8(6):10485-10497. PubMed ID: 28060759
[TBL] [Abstract][Full Text] [Related]
26. Identification of tumor microenvironment-related signature for predicting prognosis and immunotherapy response in patients with bladder cancer.
Yao Z; Zhang H; Zhang X; Zhang Z; Jie J; Xie K; Li F; Tan W
Front Genet; 2022; 13():923768. PubMed ID: 36147509
[TBL] [Abstract][Full Text] [Related]
27. Construction and verification of a novel hypoxia-related lncRNA signature related with survival outcomes and immune microenvironment of bladder urothelial carcinoma by weighted gene co-expression network analysis.
Cai D; Zhou Z; Wei G; Wu P; Kong G
Front Genet; 2022; 13():952369. PubMed ID: 36118856
[No Abstract] [Full Text] [Related]
28. Tumor Microenvironment Analysis Identified Subtypes Associated With the Prognosis and the Tumor Response to Immunotherapy in Bladder Cancer.
Zhang H; Song J; Dong J; Liu Z; Lin L; Wang B; Ma Q; Ma L
Front Genet; 2021; 12():551605. PubMed ID: 33732281
[No Abstract] [Full Text] [Related]
29. Identification and Development of Inflammatory Response-Related Genes Signature Associated With Prognosis Evaluation and Immune Status of Bladder Cancer.
Zheng H; Luo W; Li Y; Peng G; Zhou D; Tang D; Cheng J; Wu S
Front Cell Dev Biol; 2022; 10():837849. PubMed ID: 35309900
[No Abstract] [Full Text] [Related]
30. Genome-wide Exploration of a Pyroptosis-Related Long Non-Coding RNA Signature Associated With the Prognosis and Immune Response in Patients With Bladder Cancer.
Gao X; Cai J
Front Genet; 2022; 13():865204. PubMed ID: 35571063
[No Abstract] [Full Text] [Related]
31. Immunological significance of alternative splicing prognostic signatures for bladder cancer.
Li X; Yang L; Huang W; Jia B; Lai Y
Heliyon; 2022 Feb; 8(2):e08994. PubMed ID: 35243106
[TBL] [Abstract][Full Text] [Related]
32. Construction of immune-related LncRNAs classifier to predict prognosis and immunotherapy response in thymic epithelial tumors.
Su Y; Ou Y; Chen Y; Ma X
Biosci Rep; 2022 May; 42(5):. PubMed ID: 35438133
[TBL] [Abstract][Full Text] [Related]
33. Identification of an inflammation-related risk signature for prognosis and immunotherapeutic response prediction in bladder cancer.
Wang Y; Tang Y; Liu Z; Tan X; Zou Y; Luo S; Yao K
Sci Rep; 2024 Jan; 14(1):1216. PubMed ID: 38216619
[TBL] [Abstract][Full Text] [Related]
34. Identification and Quantification of Iron Metabolism Landscape on Therapy and Prognosis in Bladder Cancer.
Song X; Xin S; Zhang Y; Mao J; Duan C; Cui K; Chen L; Li F; Liu Z; Wang T; Liu J; Liu X; Song W
Front Cell Dev Biol; 2022; 10():810272. PubMed ID: 35265613
[TBL] [Abstract][Full Text] [Related]
35. Development and experimental validation of a folate metabolism-related gene signature to predict the prognosis and immunotherapeutic sensitivity in bladder cancer.
Liu X; Chen C; Xu P; Chen B; Xu A; Liu C
Funct Integr Genomics; 2023 Sep; 23(4):291. PubMed ID: 37676513
[TBL] [Abstract][Full Text] [Related]
36. Identification of a Novel PPAR Signature for Predicting Prognosis, Immune Microenvironment, and Chemotherapy Response in Bladder Cancer.
Zhu K; Deng W; Deng H; Liu X; Wang G; Fu B
PPAR Res; 2021; 2021():7056506. PubMed ID: 35027921
[TBL] [Abstract][Full Text] [Related]
37. Identifying a hypoxia related score to predict the prognosis of bladder cancer: a study with The Cancer Genome Atlas (TCGA) database.
Zhang Z; Li Q; Li A; Wang F; Li Z; Meng Y; Zhang Q
Transl Androl Urol; 2021 Dec; 10(12):4353-4364. PubMed ID: 35070817
[TBL] [Abstract][Full Text] [Related]
38. A novel signature constructed by ferroptosis-associated genes (FAGs) for the prediction of prognosis in bladder urothelial carcinoma (BLCA) and associated with immune infiltration.
Luan JC; Zeng TY; Zhang QJ; Xia DR; Cong R; Yao LY; Song LB; Zhou X; Zhou X; Chen X; Xia JD; Song NH
Cancer Cell Int; 2021 Aug; 21(1):414. PubMed ID: 34362387
[TBL] [Abstract][Full Text] [Related]
39. Prognostic implications of necroptosis-related long noncoding RNA signatures in muscle-invasive bladder cancer.
Jiang K; Wu L; Yin X; Tang Q; Yin J; Zhou Z; Yu H; Yan S
Front Genet; 2022; 13():1036098. PubMed ID: 36531246
[No Abstract] [Full Text] [Related]
40. Construction of a Novel Immune-Related mRNA Signature to Predict the Prognosis and Immune Characteristics of Human Colorectal Cancer.
Li J; Han T; Wang X; Wang Y; Chen X; Chen W; Yang Q
Front Genet; 2022; 13():851373. PubMed ID: 35401707
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
